59 results
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (2) if, in connection with any lawsuit filed
8-K
EX-10.2
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal … and (2) if, in connection with any lawsuit filed by the Executive for retaliation by the Company for reporting a suspected violation of law
8-K
EX-10.3
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (2) if, in connection with any lawsuit filed
8-K
EX-10.1
5u87nhtu0meefby
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
58sst4g0 hpjjt8t9yv
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.3
g24amm9qbsceaexy
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
425
EX-10.1
jh2csd5ebhnhfl6f74
19 May 23
Business combination disclosure
4:31pm
8-K
EX-10.1
3kq3n
19 May 23
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-10.1
ck3t06u
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-1.1
f0ntf14w
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
EX-10.1
ldlal
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
8-K
EX-10.1
0uamlauqqj
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
EX-10.2
169ofb
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
EX-10.1
d6uop19 dikmsht1
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
EX-10.1
6krr1pv7jpzzv ge8
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-10.1
qfhu0dwkj
18 Mar 20
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
5:22pm
8-K
EX-10.1
hkalbdr
13 Dec 19
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
4:19pm